Spots Global Cancer Trial Database for Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Official Title: A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer
Study ID: NCT00314782
Conditions
Study Description
Brief Summary: Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Research Site, Buffalo, New York, United States
Research Site, Greenville, South Carolina, United States
Research Site, Nashville, Tennessee, United States
Research Site, Berlin, , Germany
Research Site, Dresden, , Germany
Research Site, Rostock, , Germany
Research Site, London, , United Kingdom
Research Site, Plymouth, , United Kingdom
Research Site, Surrey, , United Kingdom
Contact Details
Name: AstraZeneca Emerging Oncology Medical Science Director, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
